Liu S S, Cai G R
Tongji Medical University, Wuhan.
Zhonghua Fu Chan Ke Za Zhi. 1991 Jan;26(1):17-20, 61.
The clinical significance of serum ribonuclease (RNase) was studied in patients with malignant tumor of the ovary, and the result was compared with serum sialic acid (SA). Serum RNase and SA level were determined in 190 women consisting of 35 normal women, 34 patients with ovarian cancer, 39 patients with other malignant gynecological tumors, 38 ovarian cancer patients with clinical remission after treatment and 44 patients with benign gynecological tumor. The sensitivity of serum RNase was 82.4% in the diagnosis of malignant tumor of the ovary. Serum RNase was positive in 42.9% of patients with minimal residual tumor and 88.9% those with residual tumors greater than 2 cm in diameter. Serum RNase assay is a simple, rapid and reliable method useful in monitoring the course of disease.
研究了血清核糖核酸酶（RNase）在卵巢恶性肿瘤患者中的临床意义，并将结果与血清唾液酸（SA）进行比较。对190名女性进行了血清RNase和SA水平测定，其中包括35名正常女性、34名卵巢癌患者、39名其他妇科恶性肿瘤患者、38名治疗后临床缓解的卵巢癌患者以及44名妇科良性肿瘤患者。血清RNase诊断卵巢恶性肿瘤的敏感性为82.4%。在微小残留肿瘤患者中，血清RNase阳性率为42.9%，在直径大于2 cm的残留肿瘤患者中为88.9%。血清RNase检测是一种简单、快速且可靠的方法，有助于监测疾病进程。
